http://www.acc.org/Feed?clinicalTopicID=45d25f86-5c8b-42a6-818b-c3998baad19a Clinical Topic Feed: Lipid Metabolism en /Latest-in-Cardiology/Journal-Scans/2026/08/05/20/14/GBD-Study-2023 The global burden attributable to elevated LDL-C has grown substantially since 1990, driven largely by population growth and aging despite significant declines in age-standardized rates, according to findings from the Global Burden of Disease Study 2023 (GBD 2023) Cholesterol Collaborators published July 29 in JAMA. 1786042800000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/08/03/10/06/ADVANCE-OUTCOMES Ralinepag, a selective prostacyclin IP receptor agonist, significantly reduced the risk of first clinical worsening compared with placebo in patients with pulmonary arterial hypertension (PAH) but was associated with more adverse-event-related treatment discontinuations, according to results of the ADVANCE OUTCOMES trial published July 28 in The Lancet. 1785862800000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/07/28/17/19/NHANES-Analyses Three studies using National Health and Nutrition Examination Survey (NHANES) data published July 20 in JAMA provide new insights into LDL-C treatment goals under the 2026 ACC/AHA Guideline on the Management of Dyslipidemia. 1785351240000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/07/20/14/38/GBD-2023 Nearly 90% of ischemic heart disease (IHD) deaths in 2023 in the U.S. were attributable to modifiable risk factors, led by high systolic blood pressure (SBP), dietary risks and high LDL-C, according to data from the Global Burden of Disease Study 2023 (GBD 2023), published July 15 in JAMA Cardiology. 1784735640000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/21/12/01/FDA-Update The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). 1784635560000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/01/12/47/eagles-eye-view-01jul2026 In this week’s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). 1782910140000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/01/01/Prioritizing-Health Earlier intervention and lower goals for LDL-C are key recommendations in the ACC/AHA Dyslipidemia Guideline, published in March – recognizing the risks of prolonged exposure to dyslipidemia leading to atherosclerotic cardiovascular disease (ASCVD). 1782907920000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/23/13/25/Combined-LDL-C-Lpa-and-hsCRP-Assessment Combined assessment of LDL-C, Lp(a) and hsCRP reflected independent pathways for identifying individuals of varied ethnicities at greater long-term risk of atherosclerotic cardiovascular disease (ASCVD), according to an analysis of the HELIUS cohort published June 24 in JACC. 1782413280000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/24/13/30/eagles-eye-view-24jun2026 In this week’s View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. 1782308100000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/17/16/52/CV-Risk-Factor Treatment of hypertension and hyperlipidemia was low among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, with less than half achieving blood pressure or glycemic control, and gaps in starting treatment were greatest among women, young adults and Hispanic adults. Furthermore, inadequate risk factor control was highest among those with the highest cardiovascular risk, according to research published June 17 in JACC. 1781716440000 Articles and Stories